Finance

Mga Listahan
FLNA:BMV
Filana Therapeutics Inc
MX$15.92
0.00%
(0.00) 1D
Okt 5, 12:05:31 PM GMT-6  ·   MXN
Lahat ng simbolo
SimboloPresyoPalitan% ng Pagbabago
Bumubuo ng mga nangungunang insight para sa FLNA...
Mkt. cap
34.02M
Avg. na dami
0.00
Dami
0.00
Mataas nang 52-wk
MX$56.00
Mababa nang 52-wk
MX$15.92
Bilang ng mga empleyado
19
Mkt. cap
34.02M
Avg. na dami
0.00
Dami
0.00
Mataas nang 52-wk
MX$56.00
Mababa nang 52-wk
MX$15.92
Bilang ng mga empleyado
19
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Profile
Filana Therapeutics, Inc. is an American pharmaceutical company based in Austin, Texas. Currently led by President and CEO Richard Barry, Filana is working on developing simufilam to treat tuberous sclerosis complex–related epilepsy. The company previously was developing simufilam as an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials. In June 2024, the United States Department of Justice charged an advisor to Cassava Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was the company's senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of the company $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. Wikipedia
Tungkol sa Filana Therapeutics Inc
CEO-
Mga Empleyado19
Itinatag1998
HeadquartersAustin, Texas, Estados Unidos
Sektor-
Mga nakaraang ulatLahat ng value sa USD
Loading Previous Earnings...
Kita
Net na kita
Lahat ng value sa USD
Set 2025
Dis 2025
Mar 2026
Hun 2026
Kita
-
-
-
-
Gastusin sa mga naibentang produkto
3.96M
3.85M
4.54M
3.30M
Halaga ng kita
3.96M
3.85M
4.54M
3.30M
Mga gastos sa pananaliksik at pag-develop
-
-
-
-
Kabuuang gastos sa pananaliksik at pag-develop
-
-
-
-
Mga gastos sa pagbebenta, pangkalahatan, at admin
7.90M
5.70M
6.62M
6.09M
Gastos sa pagpapatakbo
7.90M
5.70M
6.62M
6.09M
Kabuuang gastos sa pagpapatakbo
11.86M
9.55M
11.17M
9.39M
Kita sa pagpapatakbo
-11.86M
-9.55M
-11.17M
-9.39M
Iba pang hindi kita sa pagpapatakbo
-114.00K
39.00K
48.00K
43.00K
EBT na may mga hindi karaniwang item
-10.81M
-12.54M
-10.33M
-8.60M
EBT na hindi kasama ang mga hindi karaniwang item
-10.81M
-8.54M
-10.33M
-8.60M
Gastos sa buwis sa kita
-
-
-
-
Epektibong rate ng buwis
-
-
-
-
Iba pang gastos sa pagpapatakbo
-
-
-
-
Net na kita
-10.81M
-12.54M
-10.33M
-8.60M
Margin ng kabuuang kita
-
-
-
-
Kita bawat share
-
-
-
-
Kita sa interes at investment
1.17M
974.00K
789.00K
747.00K
Gastos sa interes
-
-
-
-
Mga net na gastos sa interes
1.17M
974.00K
789.00K
747.00K
Mga singil sa depreciation at amortization
-
-
-
-
EBITDA
-11.73M
-9.18M
-10.92M
-9.15M
Kita o pagkalugi mula sa pagbebenta ng mga asset
-
-
-
-
Posibleng magkaroon ng mga pagkakamali ang AI content. Matuto pa
Mga app ng Google